Hyzaar (Losartan Potassium, Hydrochlorothiazide)

Hyzaar is used to treat hypertension by targeting the renin‑angiotensin system and promoting diuresis.

• Essential hypertension: lowers systolic and diastolic blood pressure and reduces cardiovascular risk.
• Hypertension requiring diuretic therapy: adds fluid‑removing effect to improve blood‑pressure control.
• Hypertension with fluid retention: helps reduce extracellular volume while blocking angiotensin‑II‑mediated vasoconstriction.

• Losartan potassium selectively blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone release, while hydrochlorothiazide inhibits Na⁺/Cl⁻ reabsorption in the distal convoluted tubule, increasing urinary excretion of sodium and water. The combined actions decrease peripheral vascular resistance and plasma volume, resulting in lowered arterial pressure.

Hyzaar may cause a range of adverse reactions. Most are mild and reversible.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Fatigue or weakness
• Increased urination
• Electrolyte disturbances (e.g., low potassium)
• Mild gastrointestinal upset

Serious or Rare Side Effects

• Severe dehydration or electrolyte imbalance
• Hyperkalemia
• Acute kidney injury
• Angioedema or severe allergic reaction
• Pancreatitis
• Significant drop in blood pressure (hypotension).

Before initiating Hyzaar, consider the following safety measures.

• Blood pressure monitoring: ensure adequate control and avoid excessive hypotension.
• Renal function assessment: check serum creatinine and eGFR regularly.
• Electrolyte surveillance: monitor potassium and sodium levels, especially when combined with other diuretics.
• Pregnancy and lactation: avoid use unless benefits outweigh risks, as safety data are limited.
• Concomitant potassium supplements or potassium‑sparing agents: use with caution to prevent hyperkalemia.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Hyzaar can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid)

• Aliskiren in diabetic patients: increased risk of renal impairment.
• Potassium‑sparing diuretics or supplements: risk of hyperkalemia.
• ACE inhibitors or other ARBs: additive effect on potassium and renal function.
• Lithium: may increase lithium serum concentrations.
• NSAIDs: can blunt antihypertensive effect and affect renal function.

Moderate Interactions (Monitor Closely)

• Other antihypertensives: may cause additive blood‑pressure lowering.
• Antidiabetic agents: blood‑glucose control may improve, requiring dose adjustment.
• Cyclosporine or tacrolimus: increased risk of nephrotoxicity.
• Rifampin or other enzyme inducers: may reduce plasma levels of losartan.
• Digoxin: altered renal clearance may affect digoxin levels.